CN Patent

CN117377471A — 治疗肿瘤的联合疗法

Assigned to Kaifu Suzhou Biomedical Co ltd · Expires 2024-01-09 · 2y expired

What this patent protects

一种治疗、遏制个体的癌症、降低其严重性、降低其风险或抑制其转移，或者增强针对癌症的细胞介导的免疫应答的方法，所述方法包括向所述个体给药治疗有效量的EP4受体拮抗剂以及治疗有效量的乐伐替尼或其药学上可接受的盐。还涉及包含EP4受体拮抗剂以及乐伐替尼或其药学上可接受的盐的药物组合物或药盒。

USPTO Abstract

一种治疗、遏制个体的癌症、降低其严重性、降低其风险或抑制其转移，或者增强针对癌症的细胞介导的免疫应答的方法，所述方法包括向所述个体给药治疗有效量的EP4受体拮抗剂以及治疗有效量的乐伐替尼或其药学上可接受的盐。还涉及包含EP4受体拮抗剂以及乐伐替尼或其药学上可接受的盐的药物组合物或药盒。

Drugs covered by this patent

Patent Metadata

Patent number
CN117377471A
Jurisdiction
CN
Classification
—
Expires
2024-01-09
Drug substance claim
No
Drug product claim
No
Assignee
Kaifu Suzhou Biomedical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.